Full metadata record
DC FieldValueLanguage
dc.creatorQuirce, S. (Santiago)-
dc.creatorCosio, B.G. (Borja G.)-
dc.creatorEspaña, A. (Agustín)-
dc.creatorBlanco, R. (Ricardo)-
dc.creatorMullol, J. (J.)-
dc.creatorSantander, C. (Cecilio)-
dc.creatorPozo, V. (Victoria) del-
dc.date.accessioned2023-09-20T15:53:51Z-
dc.date.available2023-09-20T15:53:51Z-
dc.date.issued2023-
dc.identifier.citationQuirce, S.; Cosío, B. G.; España-Alonso, A. (Agustín); et al. "Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach". Frontiers in Immunology. 14, 2023, 1192284es
dc.identifier.issn1664-3224-
dc.identifier.urihttps://hdl.handle.net/10171/67277-
dc.description.abstractElevated eosinophil counts in blood and tissue are a feature of many pathological processes. Eosinophils can migrate and accumulate in a wide variety of tissues and, by infiltrating a target organ, can mediate the development of several inflammatory diseases. The normalization of eosinophilia is a common biomarker of a treatable trait and can also be used as a prognostic and predictive biomarker since it implies a reduction in type 2 inflammation that contributes to disease pathogenesis. Biological therapies targeting this cell type and its proinflammatory mediators have been shown to be effective in the management of a number of eosinophilic diseases, and for this reason they constitute a potential common strategy in the treatment of patients with various multimorbidities that present with type 2 inflammation. Various biological options are available that could be used to simultaneously treat multiple target organs with a single drug, bearing in mind the need to offer personalized treatments under the umbrella of precision medicine in all patients with eosinophil-associated diseases (EADs). In addition to reviewing these issues, we also discuss a series of perspectives addressing the management of EAD patients from a multidisciplinary approach, with the collaboration of health professionals from different specialties who manage the different multimorbidities that frequently occur in these patients. We examine the basic principles of care that this multidisciplinary approach must cover and present a multidisciplinary expert opinion regarding the ideal management of patients with EADs, from diagnosis to therapeutic approach and follow-up.-
dc.description.sponsorshipThis study received funding from AstraZeneca. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.-
dc.language.isoen-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectEosinophil-
dc.subjectMultidisciplinary management-
dc.subjectExpert opinion-
dc.subjectEosinophil-associated disease-
dc.subjectEosinophilic inflammation-
dc.titleManagement of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach-
dc.typeinfo:eu-repo/semantics/article-
dc.description.noteThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).-
dc.identifier.doi10.3389/fimmu.2023.1192284-
dadun.citation.publicationNameFrontiers in Immunology-
dadun.citation.startingPage1192284-
dadun.citation.volume14-
dc.identifier.pmid37266434-

Files in This Item:
Thumbnail
File
pdf.pdf
Description
Size
1.47 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.